Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 432

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 432
---
 Heritas Argentina and CIBIC entered into a revolving loan agreement in the aggregate amount of up to $238,742, which was made available in Argentine Pesos, and is available for disbursement through October 1, 2024. The outstanding balance of this loan as of June 30, 2024 was $0.01. On March 20, 2024 the maturity of this agreement was extended to October 1, 2028 and accrues interest at 6.5% per annum. Subsequent Events Loan Amendments and Credit Line Extensions In connection with the credit agreements with CIBIC and Bioceres described in note 20 to Omnigenics unaudited interim condensed combined financial statements as of December31, 2024, and to support ongoing operations, the subsidiary Heritas S.A.U. received financing from these credit facilities after December31, 2024, totaling $178,006: •$81,996 of financing from Bioceres S.A. On March18, 2025, Heritas Argentina amended its existing loans agreements with Bioceres S.A. to extend the two available credit lines from a total of $977,147 to $1,157,143. This implies that, as of the date of issuance of these interim condensed combined financial statements, $142,231 of said total amount of the credit lines are still available); and •$96,010 of financing from CIBIC, of which a) $9,087 were obtained using available credit lines, and b) $86,923 correspond to an additional loan provided by said borrower (with the same conditions as the existing loans as of December 2024). This implies that, as of the date of issuance of these interim condensed combined financial statements, there are not available balances of said credit lines. These related party loans bear interest at 6.5% per annum and mature in January 2028. For further details, see footnote 5 to the “ Adjustments to Unaudited Pro Forma Combined Statement of Financial Position as of December 31, 2024.” For more information, see notes 20 and 24 of OmnigenicsAI’s interim condensed combined financial statements as of December31, 2024. Second Amendment to Commercialization Agreement On February1, 2025, Heritas Argentina and CIBIC entered into a second amendment to the Commercialization Agreement. The purpose of this second amendment is to enhance our operational flexibility in Argentina. For more information, see “